202 related articles for article (PubMed ID: 12367730)
1. HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase.
Sehr P; Müller M; Höpfl R; Widschwendter A; Pawlita M
J Virol Methods; 2002 Oct; 106(1):61-70. PubMed ID: 12367730
[TBL] [Abstract][Full Text] [Related]
2. A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology.
Sehr P; Zumbach K; Pawlita M
J Immunol Methods; 2001 Jul; 253(1-2):153-62. PubMed ID: 11384677
[TBL] [Abstract][Full Text] [Related]
3. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.
Kirnbauer R; Hubbert NL; Wheeler CM; Becker TM; Lowy DR; Schiller JT
J Natl Cancer Inst; 1994 Apr; 86(7):494-9. PubMed ID: 8133532
[TBL] [Abstract][Full Text] [Related]
4. Expression of HPV-16 L1 capsomeres with glutathione-S-transferase as a fusion protein in tobacco plastids: an approach for a capsomere-based HPV vaccine.
Hassan SW; Waheed MT; Müller M; Clarke JL; Shinwari ZK; Lössl AG
Hum Vaccin Immunother; 2014; 10(10):2975-82. PubMed ID: 25483463
[TBL] [Abstract][Full Text] [Related]
5. VLP Production from Recombinant L1/L2 HPV-16 Protein Expressed in Pichia Pastoris.
Sanchooli A; Aghaiypour K; Kiasari BA; Samarbaf-Zadeh A; Ghadiri A; Makvandi M
Protein Pept Lett; 2018; 25(8):783-790. PubMed ID: 30091403
[TBL] [Abstract][Full Text] [Related]
6. Comparison of a VLP-based and GST-L1-based multiplex immunoassay to detect vaccine-induced HPV-specific antibodies in first-void urine.
Pattyn J; Panicker G; Willhauck-Fleckenstein M; Van Keer S; Téblick L; Pieters Z; Tjalma WAA; Matheeussen V; Van Damme P; Waterboer T; Unger ER; Vorsters A
J Med Virol; 2020 Dec; 92(12):3774-3783. PubMed ID: 32266996
[TBL] [Abstract][Full Text] [Related]
7. Detection of antibodies to L1, L2, and E4 proteins of human papillomavirus types 6, 11, and 16 by ELISA using synthetic peptides.
Le Cann P; Chabaud M; Leboulleux D; Mougin C; Mayelo V; Legrand MC; Calvet C; Afoutou JM; Coll-Seck AM; Coursaget P
J Med Virol; 1995 Apr; 45(4):410-4. PubMed ID: 7545211
[TBL] [Abstract][Full Text] [Related]
8. The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system.
Touze A; El Mehdaoui S; Sizaret PY; Mougin C; Muñoz N; Coursaget P
J Clin Microbiol; 1998 Jul; 36(7):2046-51. PubMed ID: 9650960
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus (HPV) L1 and L1-L2 virus-like particle-based multiplex assays for measurement of HPV virion antibodies.
Hernandez BY; Ton T; Shvetsov YB; Goodman MT; Zhu X
Clin Vaccine Immunol; 2012 Sep; 19(9):1348-52. PubMed ID: 22761294
[TBL] [Abstract][Full Text] [Related]
10. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins.
Waterboer T; Sehr P; Michael KM; Franceschi S; Nieland JD; Joos TO; Templin MF; Pawlita M
Clin Chem; 2005 Oct; 51(10):1845-53. PubMed ID: 16099939
[TBL] [Abstract][Full Text] [Related]
11. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention.
Wakabayashi MT; Da Silva DM; Potkul RK; Kast WM
Intervirology; 2002; 45(4-6):300-7. PubMed ID: 12566713
[TBL] [Abstract][Full Text] [Related]
12. A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection.
Monroy-García A; Gómez-Lim MA; Weiss-Steider B; la Rosa GP; Hernández-Montes J; Pérez-Saldaña K; Tapia-Guerrero YS; Toledo-Guzmán ME; Santiago-Osorio E; Sanchez-Peña HI; Mora-García Mde L
Virol J; 2011 Feb; 8():59. PubMed ID: 21306638
[TBL] [Abstract][Full Text] [Related]
13. Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens.
Trevisan A; Candeias JMG; Thomann P; Villa LL; Franco EL; Trottier H; The Ludwig-McGill Study Group
J Med Microbiol; 2020 Jul; 69(7):960-970. PubMed ID: 32510304
[No Abstract] [Full Text] [Related]
14. Detection of antibodies against human papillomavirus (HPV) type 16 virions by enzyme-linked immunosorbent assay using recombinant HPV 16 L1 capsids produced by recombinant baculovirus.
Le Cann P; Touze A; Enogat N; Leboulleux D; Mougin C; Legrand MC; Calvet C; Afoutou JM; Coursaget P
J Clin Microbiol; 1995 May; 33(5):1380-2. PubMed ID: 7615761
[TBL] [Abstract][Full Text] [Related]
15. Immunization with a pentameric L1 fusion protein protects against papillomavirus infection.
Yuan H; Estes PA; Chen Y; Newsome J; Olcese VA; Garcea RL; Schlegel R
J Virol; 2001 Sep; 75(17):7848-53. PubMed ID: 11483728
[TBL] [Abstract][Full Text] [Related]
16. [Specific serologic studies with a novel authentic HPV antigen (virus-like particles) for HPV-6 antibodies in gynecologic patient samples].
Heim K; Christensen ND; Höpfl R; Wartusch B; Zeimet A; Larcher C; Ruth N; Bergant A; Pirschner G; Dierich MP
Gynakol Geburtshilfliche Rundsch; 1995; 35 Suppl 1():25-31. PubMed ID: 8672922
[TBL] [Abstract][Full Text] [Related]
17. Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus.
Robbins HA; Li Y; Porras C; Pawlita M; Ghosh A; Rodriguez AC; Schiffman M; Wacholder S; Kemp TJ; Gonzalez P; Schiller J; Lowy D; Esser M; Matys K; Quint W; van Doorn LJ; Herrero R; Pinto LA; Hildesheim A; Waterboer T; Safaeian M
BMC Infect Dis; 2014 Mar; 14():120. PubMed ID: 24588945
[TBL] [Abstract][Full Text] [Related]
18. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.
Varsani A; Williamson AL; de Villiers D; Becker I; Christensen ND; Rybicki EP
J Virol; 2003 Aug; 77(15):8386-93. PubMed ID: 12857908
[TBL] [Abstract][Full Text] [Related]
19. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.
Park JS; Oh YK; Kang MJ; Kim CK
J Med Virol; 2003 Aug; 70(4):633-41. PubMed ID: 12794729
[TBL] [Abstract][Full Text] [Related]
20. Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer.
Baek JO; Seo JW; Kwon O; Park SM; Kim CH; Kim IH
Enzyme Microb Technol; 2012 Mar; 50(3):173-80. PubMed ID: 22305172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
